Fluorine-18 prostate-specific membrane antigen-1007-avid indeterminate bone lesions in prostate cancer: clinical and PET/CT features to predict outcomes and prognosis-Reference-Cited by-同舟云学术

Fluorine-18 prostate-specific membrane antigen-1007-avid indeterminate bone lesions in prostate cancer: clinical and PET/CT features to predict outcomes and prognosis

Published:2024-05 Issue:5 Volume:79 Page:346-353
ISSN:0009-9260
Container-title:Clinical Radiology
language:en
Short-container-title:Clinical Radiology

Author:

Luo L.,Wang Z.,Wang X.,Gao J.,Zheng A.,Duan X.^ORCID

Funder

National Natural Science Foundation of China

Natural Science Foundation of Shaanxi Province

Publisher

Elsevier BV

Reference29 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries;Sung;CA Cancer J Clin,2021

2. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer;Ghosh;J Cell Biochem,2004

3. Targeted therapies for prostate cancer against the prostate specific membrane antigen;Elsässer-Beile;Curr Drug Targets,2009

4. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent;Mottet;Eur Urol,2017

5. Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer;Ferraro;Eur J Nucl Med Mol Imaging,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [¹⁸F]PSMA-1007 PET/CT;Journal of Nuclear Medicine;2024-09-05

2. Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review—Part 1 oncological setting;Clinical and Translational Imaging;2024-08-05